/
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and a…
The business is unprofitable at the operating level (-10386.54% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 550.0% YoY with margins expanding 155337.5pp.
Negative free cash flow of -$130M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$1M
▲ +550.0% YoY
Net Income (TTM)
-$130M
▼ -108.3% YoY
Op. Margin
-10386.54%
▲ +155337.5pp YoY
ROIC
-63.23%
▲ +49.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$132M
▲ +34.1% YoY
Op. Cash Flow (TTM)
-$132M
▲ +33.2% YoY
Net Debt
$19M
Cash & Equiv.
$162M
Continue Research